Identifying patients at risk of complete nonresponse in the outpatient treatment of depression
HL Van, J Dekker, J Peen, G Van Aalst… - Psychotherapy and …, 2008 - karger.com
Background: Although complete nonresponse in depression treatment is considered to be a
major problem in clinical practice, research in this area is very limited. The objective of this …
major problem in clinical practice, research in this area is very limited. The objective of this …
Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression
Failure to achieve an adequate response after initial antidepressant treatment in patients
with depression is common and remains a clinical challenge. In recent years, some atypical …
with depression is common and remains a clinical challenge. In recent years, some atypical …
Sertraline with desvenlafaxine and sertraline with mirtazapine as treatment initiation in MDD patients with moderate to severe depression and effect on inflammatory …
N Arockiaraj, R Gupta, R Ahmad, S Halder… - … Journal of Psychiatry …, 2024 - Taylor & Francis
Background This study evaluated the effect of sertraline with desvenlafaxine and sertraline
with mirtazapine on HAM-D score and inflammatory markers (IL-6 and TNF-α levels) in …
with mirtazapine on HAM-D score and inflammatory markers (IL-6 and TNF-α levels) in …
Aripiprazole in major depression and mania: meta-analyses of randomized placebo-controlled trials
B Arbaizar, T Dierssen-Sotos, I Gómez-Acebo… - General hospital …, 2009 - Elsevier
OBJECTIVE: We performed meta-analyses to obtain pooled estimates from controlled
clinical trials on the efficacy of aripiprazole in major depression disorder and manic phase of …
clinical trials on the efficacy of aripiprazole in major depression disorder and manic phase of …
A randomized, double-blind, placebo-controlled phase 2 study of the augmentation of a nicotinic acetylcholine receptor partial agonist in depression: is there a …
This randomized, double-blind, placebo-controlled trial evaluated the efficacy of CP-
601,927, an α4β2 nicotinic acetylcholine receptor partial agonist and an augmenting agent …
601,927, an α4β2 nicotinic acetylcholine receptor partial agonist and an augmenting agent …
Expectancy in double-blind placebo-controlled trials: an example from alcohol dependence
Background: Double-blind placebo-controlled trials are intended to control for the impact of
expectancy on outcomes. Whether they always achieve this is, however, questionable …
expectancy on outcomes. Whether they always achieve this is, however, questionable …
[PDF][PDF] Novel augmentation strategies in major depression
K Martiny - Dan Med J, 2017 - researchgate.net
The bright light study investigated the use of bright white light to augment antidepressant
drug therapy in patients with a major depressive episode. Light is ubiquitous and linked to …
drug therapy in patients with a major depressive episode. Light is ubiquitous and linked to …
Depressive Störungen
G Laux - … , Psychotherapie: Band 1: Allgemeine Psychiatrie 1 …, 2017 - Springer
Zusammenfassung Das Spektrum unipolarer depressiver Erkrankungen macht den
Hauptteil affektiver Störungen aus und gehört mit einer Inzidenz von ca. 8–20% zu den …
Hauptteil affektiver Störungen aus und gehört mit einer Inzidenz von ca. 8–20% zu den …
Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study
GI Papakostas, A Clain, VE Ameral, L Baer… - International clinical …, 2010 - journals.lww.com
Anxious depression, defined as major depressive disorder (MDD) accompanied by high
levels of anxiety, seems to be both common and difficult to treat, with antidepressant …
levels of anxiety, seems to be both common and difficult to treat, with antidepressant …
Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies
M Fava, SR Wisniewski, ME Thase… - Journal of clinical …, 2009 - journals.lww.com
In 2 identical multicenter, double-blind, placebo-controlled trials, an 8-week prospective
treatment phase to ensure inadequate response to standard antidepressants was followed …
treatment phase to ensure inadequate response to standard antidepressants was followed …